MedTrace Logo

Phase 1 Clinical Study of GenSci155 Injection in Healthy Adults

NCT07638800 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2026-06-10

No results posted yet for this study

Summary

This is a Phase 1, single-center, randomized, double-blind, placebo-controlled, single and multiple intravenous ascending dose clinical study to evaluate the safety, tolerability, PK, immunogenicity, and biomarker characteristics of GenSci155 after a single or multiple intravenous injection in healthy Chinese adult trial participants.

Conditions

  • Healthy Adult Trial Participants

Interventions

DRUG

GenSci155 Injection

Part 1 consists of a total of 6 dose cohorts，Part 2 consists of a total of 3 dose cohorts

DRUG

Placebo

Part 1 consists of a total of 6 dose cohorts，Part 2 consists of a total of 3 dose cohorts

Sponsors & Collaborators

  • Changchun GeneScience Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-07-28
Primary Completion
2027-04-16
Completion
2027-07-28

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07638800 on ClinicalTrials.gov